CELU
Celularity Inc
$0.8120
-6.88%
$19.9M
No data for this timeframe.
Vol
Market Cap$19.9M
Cap SizeNano Cap
Inst. Holders3 funds
Inst. Value$753.9K
Inst. Activity1 buys / 3 sells
Reddit Sentiment50° Neutral
SEC Reports1
Press Releases4
Recent Activity
Jun 8, 2026
earnings_calendar
CELU Q1 2026 Earnings Scheduled — 2026-06-08
May 29, 2026
Press
Celularity disclosed a Nasdaq late filing notice for its overdue Q1 2026 10-Q. The delayed filing triggers a 60-day cure
Impact 6/10
Apr 21, 2026
Press
{
"summary": "Celularity Inc. (CELU) announced the closing of a transaction with NexGel, Inc., selling its biomaterial
Impact 5/10
Apr 13, 2026
Insider
Brigido Stephen sold 821 shares
Pres., Functional Regeneration @ $0.00 ($0.00)
Apr 13, 2026
Insider
Brigido Stephen sold 268 shares
Pres., Functional Regeneration @ $1.28 ($343.04)
Apr 13, 2026
Insider
Brigido Stephen sold 821 shares
Pres., Functional Regeneration @ $0.00 ($0.00)
Mar 5, 2026
SEC
Celularity Inc. announced the departure of Joseph DosSantos as SVP, Finance and Acting CFO for personal reasons, and the
8-K — Impact 3/10
Inst.
WELLS FARGO & COMPANY/MN — DOUBLED
2,500 shares ($2.8K)
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Sep 9, 2025 | WBB Securities | UPGRADE | Hold → Buy |
| Aug 18, 2025 | WBB Securities | INITIATE | Speculative Buy |
Latest Reports
BEARISH
Press
6/10
Celularity disclosed a Nasdaq late filing notice for its overdue Q1 2026 10-Q. The delayed filing triggers a 60-day cure
May 29, 2026
NEUTRAL
8-K
3/10
Celularity Inc. announced the departure of Joseph DosSantos as SVP, Finance and Acting CFO for personal reasons, and the
Mar 5, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $751.1K | ADD |
| WELLS FARGO & COMPANY/MN | $2.8K | DOUBLED |
| BANK OF AMERICA CORP | $31.00 | NEAR_EXIT |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 13, 2026 | Brigido Stephen | M | $0.00 |
| Apr 13, 2026 | Brigido Stephen | F | $343.04 |
| Apr 13, 2026 | Brigido Stephen | M | $0.00 |
| Apr 13, 2026 | Hariri Robert | M | $0.00 |
| Apr 13, 2026 | Hariri Robert | F | $1.5K |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
3 institutional holders with $753.9K total value (679,178 shares) as of 2025-Q4. Top holders: VANGUARD, WELLS, BANK. Net selling activity: 3 institutions trimmed/exited vs 1 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 676,650 | $751.1K | 99.6% | ADD +35.3% |
| 2 | WELLS FARGO & COMPANY/MN | 2,500 | $2.8K | 0.4% | DOUBLED +400.0% |
| 3 | BANK OF AMERICA CORP /DE/ | 28 | $31.00 | 0.0% | NEAR_EXIT -99.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| WELLS FARGO & COMPANY/MN | DOUBLED | 500 | 2,500 | +400.0% | $2.8K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 37,027 | 28 | -99.9% | $31.00 | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 16,204 | 0 | -100.0% | $0.00 | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 42,000 | 0 | -100.0% | $0.00 | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 500,132 | 676,650 | +35.3% | $1.4M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 12,200 | 42,000 | +244.3% | $86.9K | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 100 | 3,000 | +2900.0% | $6.2K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 2,277 | 37,300 | +1538.1% | $73.1K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 36,380 | 16,204 | -55.5% | $31.8K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 12,200 | — | $23.9K | 2025-Q2 |
| MORGAN STANLEY | DOUBLED | 50 | 100 | +100.0% | $196.00 | 2025-Q2 |
| CITADEL ADVISORS LLC | ADD | 38,800 | 59,846 | +54.2% | $103.5K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 11,000 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 18,000 | 38,800 | +115.6% | $80.7K | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 23,380 | 11,000 | -53.0% | $22.9K | 2024-Q4 |
| UBS Group AG | NEAR_EXIT | 6,017 | 1,215 | -79.8% | $2.5K | 2024-Q4 |
| MORGAN STANLEY | NEAR_EXIT | 350 | 50 | -85.7% | $149.00 | 2024-Q3 |
3 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 13, 2026 | Brigido Stephen | Pres., Functional Regeneration | M | 821 | $0.00 | $0.00 |
| Apr 13, 2026 | Brigido Stephen | Pres., Functional Regeneration | F | 268 | $1.28 | $343.04 |
| Apr 13, 2026 | Brigido Stephen | Pres., Functional Regeneration | M | 821 | $0.00 | $0.00 |
| Apr 13, 2026 | Hariri Robert J | Chief Executive Officer | M | 3,281 | $0.00 | $0.00 |
| Apr 13, 2026 | Hariri Robert J | Chief Executive Officer | F | 1,182 | $1.28 | $1.5K |
| Apr 13, 2026 | Hariri Robert J | Chief Executive Officer | M | 3,281 | $0.00 | $0.00 |
| Apr 13, 2026 | Haines John R | Senior Exec Vice President | M | 1,641 | $0.00 | $0.00 |
| Apr 13, 2026 | Haines John R | Senior Exec Vice President | F | 583 | $1.28 | $746.24 |
| Apr 13, 2026 | Haines John R | Senior Exec Vice President | M | 1,641 | $0.00 | $0.00 |
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 3.0/10.
BEARISH
6/10
Celularity disclosed a Nasdaq late filing notice for its overdue Q1 2026 10-Q. The delayed filing tr
May 29, 2026
NEUTRAL
5/10
{
"summary": "Celularity Inc. (CELU) announced the closing of a transaction with NexGel, Inc., sel
Apr 21, 2026
BEARISH
6/10
Celularity Inc. received a Nasdaq delisting notice due to its failure to file its 2025 Form 10-K on
Apr 17, 2026
MIXED
6/10
Celularity Inc. announced a strategic commercialization partnership with NEXGEL, Inc., licensing its
Mar 12, 2026
Historical analyst distribution (last covering-analyst action Sep 2025): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2024-03-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2024-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
1 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Sep 9, 2025 | WBB Securities | UPGRADE | Hold | Buy |
| Aug 18, 2025 | WBB Securities | INITIATE | — | Speculative Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
0 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 15, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 15, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
CELU Stem Cell Company Near all time lows.
▲ 1
💬 1
⚡ 0.5
Jun 8, 2026
earnings_calendar
CELU Q1 2026 Earnings Scheduled — 2026-06-08
Jun 3, 2026
activist
Celularity Releases CEO Letter to Shareholders
<p align="left">FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ("Celularity" or the "Company"), a longevity-fo
Jun 2, 2026
Clinical Trial
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
Phase Phase 2 — TERMINATED
May 29, 2026
activist
Celularity Receives Nasdaq Notice Regarding Form 10-Q
<p>FLORHAM PARK, N.J., May 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a longevity-focused regenerative and cellula
May 7, 2026
earnings_calendar
CELU Q4 2025 Earnings After Market Close — 2026-05-07
May 1, 2026
activist
Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation
Company advances focused strategy, strengthens balance sheet and positions business for long-term growth <pre>Company advances focused strategy, stren
Apr 21, 2026
m_and_a
Celularity Announces Closing of Transaction with NexGel
<p>FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellul
Apr 17, 2026
activist
Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
<p>FLORHAM PARK, N.J., April 17, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a longevity-focused regenerative and cellu
Mar 12, 2026
contract
Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities
<p align="left">FLORHAM PARK, N.J., March 12, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerativ
Mar 10, 2026
other
Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy
<p>FLORHAM PARK, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellula